An interventional study of Exercise in Cirrhosis With Hepatocellular Carcinoma, sponsored by University Hospital, Clermont-Ferrand. Recruiting at 2 sites in France. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by University Hospital, Clermont-Ferrand · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 284 studies in Carcinoma, Hepatocellular with a site in France — 54 open to participants now, 85 under way, 14 of them phase 3. Carcinoma, Hepatocellular · France.
Among the 284 studies in Carcinoma, Hepatocellular with a site in France, this one is the 202nd largest by planned enrollment of the 215 interventional ones that give a count, is one of 8 that started in 2026, is one of 56 with no phase, reaches primary completion later than 57 of the 84 other live ones, and was the 277th registered.
3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.
Browse Carcinoma, Hepatocellular studies →54 of the 284 studies in Carcinoma, Hepatocellular with a site in France are open now. Recruiting first, the newest first:
Mark C Burgmans, MD PhD · Sites in France, Netherlands
Ages 18+
University Hospital, Angers · Sites in France
Ages 18+ · Healthy volunteers
CatalYm GmbH · Sites in France, United States, Germany and 4 more countries
Ages 18–100
Bristol-Myers Squibb · Sites in France, United States, Australia and 11 more countries
Ages 18+
Center Eugene Marquis · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
284 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 50 · Phase 2 80 · Phase 3 56 · Phase 4 4
First in 2000; this study’s year is marked. 8 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 12 is below the median of 53 across 2,623 interventional studies indexed under Carcinoma, Hepatocellular.
Median enrollment 136 across the 215 interventional studies, 209 across the 67 observational. Of the 174 that completed or were terminated, 54 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
117 of 284 have an industry lead sponsor. The 10 most frequent:
University Hospital, Clermont-Ferrand is the lead sponsor of 859 studies on the registry; 177 are open to participants now.
University Hospital, Clermont-Ferrand has 1 study filed under Carcinoma, Hepatocellular — fewer than ten, so there is no comparison to draw.
22 of the studies in Carcinoma, Hepatocellular with a site in France that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03017326Phase 3University of BirminghamPaediatric Hepatic International Tumour Trial | 2026-12-31 |
| NCT06109272Phase 3AbbVieA Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) | 2027-01 |
| NCT04803994Phase 3Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestThe ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma | 2027-07 |
| NCT05822752AbbVieStudy to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC) | 2026-11 |
| NCT05911633Terumo Europe N.V.BioPearl™ Microspheres Loaded With Doxorubicin for the Treatment of Unresectable Hepatocellular Carcinoma (HCC) | 2026-11-30 |
Add all 22 to your calendar (.ics) → With an account.
Among the 284 studies in Carcinoma, Hepatocellular with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main purpose of the study is to characterize the production of hepatokines (FGF21 and Follistatin) in response to a submaximal exercise on an ergocycle, in patients with hepatocellular carcinoma. The effect of exercise on hepatokines and metabolites production in liver cancer patients is not known. Studying this production could help to provide relevant recommendations for training programming in these patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A single study visit will be required, during which the following will be caried out: * an assessment of physical condition: lower limb isometric strength test, liver frailty index, short physical performance battery, ultrasound assessment of quadriceps muscle mass * a 30-minutes exercise session on a bicycle (with heart rate monitor and gas exchange analyzer) * 3 fasting blood tests (before, at the end and 1 hour after the exercise) to assess the production of hepatokines and metabolites * measurements of perceived fatigue, muscle pain and effort (before, at the end and 1 hour after the exercise). Snacks will be served afterwards.
Other: Exercise
30-minutes exercise on a bicycle with heart rate monitor and gas exchange analyzer.
Systemic hepatokines rates (FGF-21 and follistatin)
Blood samples
Time frame: Baseline (pre-exercise), immediately after exercise, 1 hour after the end of exercise
Muscle pain assessment
Visual analog scale. Score from 0 (total absence of muscle pain) to 10 (maximum muscle pain).
Time frame: Baseline (pre-exercise), immediately after exercise, 1 hour after the end of exercise
Fatigue assessment
Visual analog scale. Score from 0 (total absence of fatigue) to 10 (maximum fatigue).
Time frame: Baseline (pre-exercise), immediately after exercise, 1 hour after the end of exercise
Perception of effort assessment
Borg scale
Time frame: Baseline (at the beginning), periprocedural (middle of exercise), immediately after exercise
Production of metabolites
Blood samples
Time frame: Baseline (pre-exercise), immediately after exercise, 1 hour after the end of exercise
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2026 (actual). Primary completion is estimated for Apr 2028, 21 months after the start.
Of 361 non-industry interventional studies with no phase under Carcinoma, Hepatocellular, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 76. This study's planned 21 months is below that.
Counting every sponsor, half of 385 studies reached it within 47 months; a quarter within 23 and three quarters within 75.
Start moved once since we started tracking on Sep 25, 2026: Dec 2025 → Jul 2026, on Nov 9, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Clermont-Ferrand →